Edition:
United Kingdom

Eagle Pharmaceuticals Inc - On Feb 20, U.S. FDA, Issued Decision In Favor Of Co, Regarding Scope Of Exclusivity For Bendeka - SEC Filing


Thursday, 21 Feb 2019 

Feb 21 (Reuters) - Eagle Pharmaceuticals Inc ::EAGLE PHARMACEUTICALS INC - ON FEB 20, U.S. FDA, ISSUED DECISION IN FAVOR OF CO, REGARDING SCOPE OF EXCLUSIVITY FOR BENDEKA™ - SEC FILING.EAGLE PHARMACEUTICALS - PURSUANT TO FDA DECISION, NO BENDAMUSTINE PRODUCT MAY LAUNCH IN U.S. UNTIL DEC. 7, 2022 UNLESS CLINICALLY SUPERIOR TO BENDEKA. 

Company Quote

53.54
0.65 +1.23%
9:00pm BST